<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961894</url>
  </required_header>
  <id_info>
    <org_study_id>REX-US-2017-001</org_study_id>
    <nct_id>NCT02961894</nct_id>
  </id_info>
  <brief_title>Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization</brief_title>
  <acronym>REVEAL</acronym>
  <official_title>Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rex Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rex Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the Revolution™ Peripheral Atherectomy System in&#xD;
      the treatment of infrainguinal lower extremity peripheral arterial occlusive disease.&#xD;
&#xD;
      This Atherectomy system will be used on eligible patients with stenosis of at least 70%&#xD;
      diameter reduction to evaluate the change in stenosis after the procedure (effectiveness) and&#xD;
      the presence of any major adverse events (safety) for up to 30 days after the procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study intends to enroll up to 121 subjects at up to 18 investigational sites in the&#xD;
      United States. This is a single-arm study of the Revolution™ Peripheral Atherectomy System in&#xD;
      subjects with peripheral arterial disease (PAD).&#xD;
&#xD;
      The primary safety endpoint is freedom from 30-day Major Adverse Events (MAE), defined as the&#xD;
      composite of all-cause mortality, clinically-driven target lesion revascularization (TLR),&#xD;
      major target limb amputation, major target vessel perforation requiring surgical or&#xD;
      endovascular repair and clinically-significant distal embolization in the target limb; as&#xD;
      adjudicated by the independent Clinical Events Committee (CEC).&#xD;
&#xD;
      The primary effectiveness endpoint is technical success, defined by ≤50% diameter stenosis&#xD;
      after atherectomy with the Revolution™ Peripheral Atherectomy System and prior to adjunctive&#xD;
      therapy, as measured by the independent core laboratory on the post-atherectomy contrast&#xD;
      angiogram. Effectiveness will be assessed for investigator-identified target lesions and will&#xD;
      be calculated as a binary variable as the proportion of target lesions with technical&#xD;
      success.&#xD;
&#xD;
      The following will be assessed as secondary endpoints of the study:&#xD;
&#xD;
        1. Change in % stenosis after treatment with Revolution™ Peripheral Atherectomy System,&#xD;
           determined after atherectomy and prior to other adjunctive therapies, as measured by the&#xD;
           angiographic core laboratory.&#xD;
&#xD;
        2. Procedural success as defined by target lesion residual stenosis of &lt;30% at the&#xD;
           conclusion of the index procedure, after atherectomy and any adjunctive endovascular&#xD;
           treatment, as measured by the angiographic core laboratory.&#xD;
&#xD;
        3. Assessment of the individual components of the primary safety endpoint (MAE); including&#xD;
           all-cause mortality, major target limb amputation, clinically significant distal&#xD;
           embolization, major target vessel perforation requiring surgical or endovascular repair,&#xD;
           and clinically-driven TLR, measured through 30 days and at 6 months.&#xD;
&#xD;
        4. Minor unplanned target limb amputation rate through 30 days and 6 months;&#xD;
&#xD;
        5. Myocardial infarction through 30 days and 6 months;&#xD;
&#xD;
        6. Incidence of target vessel revascularization (TVR) through 30 days and 6 months;&#xD;
&#xD;
        7. Frequency of angiographic procedural distal embolization (symptomatic) in the target&#xD;
           limb as confirmed angiographically by the core laboratory;&#xD;
&#xD;
        8. Primary patency of the target lesion at 30 days and 6 months, determined by duplex&#xD;
           ultrasound or angiography;&#xD;
&#xD;
        9. Primary-assisted patency of the target lesion at 30 days and 6 months, determined by&#xD;
           duplex ultrasound or angiography;&#xD;
&#xD;
       10. Secondary patency of the target lesion at 30 days and 6 months, determined by duplex&#xD;
           ultrasound or angiography.&#xD;
&#xD;
      Subjects with symptomatic PAD eligible for treatment with the Revolution™ Peripheral&#xD;
      Atherectomy System with atherosclerotic lesions of the superficial femoral, popliteal and&#xD;
      tibial arteries will be eligible for inclusion in the study.&#xD;
&#xD;
      A performance goal of 80% for safety and 76% for effectiveness has been established from&#xD;
      prior studies. Enrollment of 121 subjects will provide 90% power, based upon a one-sided&#xD;
      97.5% exact binomial test, an anticipated 30-day MAE rate of 9%, acute technical success of&#xD;
      86%, and a 30-day attrition rate of approximately 10%.&#xD;
&#xD;
      The regulatory submission will be based on an approximate sample size of 121 subjects.&#xD;
      Assuming a lesion-to-subject ratio of 1.5, approximately 165 target lesions will be evaluable&#xD;
      for the primary effectiveness endpoint. Subset analyses will be performed for device&#xD;
      effectiveness for superficial femoral/popliteal and tibial artery target lesions.&#xD;
&#xD;
      Pre-Enrollment procedures include testing, reviewing Medical history, physical examination&#xD;
      with vital signs and directed peripheral vascular examination, laboratory assessment,&#xD;
      ankle-brachial or toe-brachial index, and patient-reported outcome measures. The diagnostic&#xD;
      angiogram at time of the planned index procedure is performed prior to the point of&#xD;
      enrollment in the study; eligibility is, in part, based upon the anatomic findings of the&#xD;
      angiogram.&#xD;
&#xD;
      Subjects will have required follow-up evaluations at the following time points:&#xD;
&#xD;
        1. Discharge;&#xD;
&#xD;
        2. 1 month post index procedure;&#xD;
&#xD;
        3. 6 months post index procedure;&#xD;
&#xD;
      Follow-Up Data Collection:&#xD;
&#xD;
        1. Adverse Events at the index procedure, hospital discharge, and through 6 months;&#xD;
&#xD;
        2. Rutherford Classification at 1 and 6 months;&#xD;
&#xD;
        3. Ankle-brachial or toe-brachial index at 1 and 6 months;&#xD;
&#xD;
        4. Duplex ultrasound of the target vessel at 1 and 6 months.&#xD;
&#xD;
      An independent Clinical Events Committee (CEC) will review all primary safety endpoint&#xD;
      events, unanticipated adverse device effects, and other important safety occurrences as&#xD;
      specified in the CEC Charter. Additionally, an independent Data Safety Monitoring Board&#xD;
      (DSMB) will review safety data from the study at predetermined time points and as deemed&#xD;
      necessary by the Sponsor or the DSMB Chair. The DSMB will make recommendations on protocol&#xD;
      modifications and continuation of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Actual">September 20, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoint: Number of Participants With Freedom From Major Adverse Events</measure>
    <time_frame>30-Day</time_frame>
    <description>Freedom from Major Adverse Events is defined as the composite of all-cause mortality, clinically-driven target lesion revascularization (TLR), major target limb amputation, major target vessel perforation requiring surgical or endovascular repair, and clinically-significant distal embolization in the target limb; as adjudicated by an independent Clinical Events Committee The primary safety endpoint is freedom from 30-day Major Adverse Events (MAE), defined as the composite of all-cause mortality, clinically-driven target lesion revascularization (TLR), major target limb amputation, major target vessel perforation requiring surgical or endovascular repair and clinically-significant distal embolization in the target limb; as adjudicated by the independent Clinical Events Committee (CEC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness Endpoint: Technical Success</measure>
    <time_frame>1-Day</time_frame>
    <description>Technical success is defined by ≤50% diameter stenosis after atherectomy with the Revolution™ Peripheral Atherectomy System and prior to adjunctive therapy, as measured by the independent core laboratory on the post-atherectomy contrast angiogram. Effectiveness will be assessed for investigator-identified target lesions and will be calculated as a binary variable as the percentage of target lesions with technical success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR) Rate</measure>
    <time_frame>30 Days</time_frame>
    <description>Target Lesion Revascularization (TLR) rate through 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in % Stenosis</measure>
    <time_frame>1-Day</time_frame>
    <description>Change in % stenosis after treatment with Revolution™ Peripheral Atherectomy System, determined after atherectomy and prior to other adjunctive therapies, as measured by the angiographic core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>1-Day</time_frame>
    <description>Procedural success as defined by target lesion residual stenosis of &lt;30% at the conclusion of the index procedure, after atherectomy and any adjunctive endovascular treatment, as measured by the angiographic core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Combined Components of the Primary Safety Endpoint, Freedom From MAE</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the total combined components of the primary safety endpoint (Freedom from MAE); including all-cause mortality, major target limb amputation, clinically significant distal embolization, major target vessel perforation requiring surgical or endovascular repair, and clinically-driven TLR, measured through 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Target Lesion Revascularization (TLR) Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from Target Lesion Revascularization (TLR) rate through 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Myocardial Infarction</measure>
    <time_frame>30 Days</time_frame>
    <description>Freedom from Myocardial infarction through 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Myocardial Infarction</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from Myocardial infarction through 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Target Vessel Revascularization (TVR) Rate</measure>
    <time_frame>30 Days</time_frame>
    <description>Freedom from incidence of target vessel revascularization (TVR) through 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Target Vessel Revascularization (TVR) Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from incidence of target vessel revascularization (TVR) through 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Angiographic Procedural Distal Embolization</measure>
    <time_frame>1-Day</time_frame>
    <description>Freedom from angiographic procedural distal embolization (symptomatic) in the target limb as confirmed angiographically by the core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>30 Days, 6 months</time_frame>
    <description>Primary patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Primary Patency</measure>
    <time_frame>30 Days, 6 months</time_frame>
    <description>Primary-assisted patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>30 Days, 6 months</time_frame>
    <description>Secondary patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Revolution Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revolution™ Peripheral Atherectomy System</intervention_name>
    <description>The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
    <arm_group_label>Revolution Treatment Arm</arm_group_label>
    <other_name>Revolution Peripheral Atherectomy System</other_name>
    <other_name>Percutaneous Transluminal Atherectomy</other_name>
    <other_name>Rotational Atherectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years;&#xD;
&#xD;
          2. Willing and able to provide informed consent.&#xD;
&#xD;
          3. Ability to take at least one form of anti-platelet therapy.&#xD;
&#xD;
          4. Rutherford categories 2 to 5 in the target limb.&#xD;
&#xD;
          5. Lesions to be treated with the study device must be located in the same limb.&#xD;
&#xD;
          6. Target lesion(s) located within the superficial femoral, popliteal or tibial arteries.&#xD;
&#xD;
          7. Target lesion(s) with stenosis ≥70% diameter reduction as measured by site-reported&#xD;
             angiography.&#xD;
&#xD;
          8. Target lesion length(s) ≤150 mm.&#xD;
&#xD;
          9. Target lesions(s) with reference vessel diameter (proximal and distal to target&#xD;
             lesion) ≥2.0 mm and ≤4.0 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects in whom amputation above the ankle is necessary, irrespective of the success&#xD;
             of revascularization.&#xD;
&#xD;
          2. In-stent restenosis within the target lesion.&#xD;
&#xD;
          3. Flow-limiting dissection, Type C or greater.&#xD;
&#xD;
          4. Target lesions within an autogenous or prosthetic bypass graft.&#xD;
&#xD;
          5. History of an endovascular procedure or open vascular reconstruction in the index limb&#xD;
             within the last 30 days, including thrombolytic therapy.&#xD;
&#xD;
          6. Any open vascular surgical procedure planned in the target limb or endovascular&#xD;
             procedures planned in the target vessel within 30 days after the index procedure.&#xD;
&#xD;
          7. Kidney disease of sufficient severity, in the Investigator's opinion, to&#xD;
             contraindicate lower extremity angiography using standard or alternate contrast agents&#xD;
             as per the local Standard of Care.&#xD;
&#xD;
          8. Pregnancy or breast feeding. A woman of child-bearing potential must have a negative&#xD;
             pregnancy test within one week of index procedure.&#xD;
&#xD;
          9. Myocardial infarction or stroke within 2 months of enrollment.&#xD;
&#xD;
         10. Contraindication to antiplatelet, anticoagulant, or thrombolytic therapy.&#xD;
&#xD;
         11. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet&#xD;
             count &lt; 125,000/μL, known coagulopathy, or INR &gt; 1.5.&#xD;
&#xD;
         12. Known allergy to contrast agents or medications used to perform endovascular&#xD;
             intervention that cannot be adequately pretreated in the opinion of the investigator.&#xD;
&#xD;
         13. History of heparin-induced thrombocytopenia.&#xD;
&#xD;
         14. Psychiatric disorder which, according to the investigator, has potential to interfere&#xD;
             with provision of informed consent, completion of tests, therapy, or follow-up.&#xD;
&#xD;
         15. Clinical/angiographic evidence of distal embolization or acute thrombus.&#xD;
&#xD;
         16. Significant stenosis (&gt;50% diameter reduction) or occlusion of inflow vessels that was&#xD;
             not successfully treated (&lt;50% residual stenosis without flow limiting dissection)&#xD;
             before the study intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey G Carr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Associates of East Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Ouriel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Syntactx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vascular Breakthroughs</name>
      <address>
        <city>Darien</city>
        <state>Connecticut</state>
        <zip>06820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular and Interventional</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Health</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Outpatient Vascular Institute</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Access Center</name>
      <address>
        <city>Mays Landing</city>
        <state>New Jersey</state>
        <zip>08330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Heart and Vascular</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Vein &amp; Vascular</name>
      <address>
        <city>Bradford</city>
        <state>Pennsylvania</state>
        <zip>16701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Area Research, LLC</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Vascular Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Heart</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFW Vascular Group</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Heart and Vascular</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rexmedical.com/</url>
    <description>RexMedical.com</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherectomy</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02961894/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02961894/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Revolution Treatment Arm</title>
          <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Revolution Treatment Arm</title>
          <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Endpoint: Number of Participants With Freedom From Major Adverse Events</title>
        <description>Freedom from Major Adverse Events is defined as the composite of all-cause mortality, clinically-driven target lesion revascularization (TLR), major target limb amputation, major target vessel perforation requiring surgical or endovascular repair, and clinically-significant distal embolization in the target limb; as adjudicated by an independent Clinical Events Committee The primary safety endpoint is freedom from 30-day Major Adverse Events (MAE), defined as the composite of all-cause mortality, clinically-driven target lesion revascularization (TLR), major target limb amputation, major target vessel perforation requiring surgical or endovascular repair and clinically-significant distal embolization in the target limb; as adjudicated by the independent Clinical Events Committee (CEC).</description>
        <time_frame>30-Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Participants With Freedom From Major Adverse Events</title>
          <description>Freedom from Major Adverse Events is defined as the composite of all-cause mortality, clinically-driven target lesion revascularization (TLR), major target limb amputation, major target vessel perforation requiring surgical or endovascular repair, and clinically-significant distal embolization in the target limb; as adjudicated by an independent Clinical Events Committee The primary safety endpoint is freedom from 30-day Major Adverse Events (MAE), defined as the composite of all-cause mortality, clinically-driven target lesion revascularization (TLR), major target limb amputation, major target vessel perforation requiring surgical or endovascular repair and clinically-significant distal embolization in the target limb; as adjudicated by the independent Clinical Events Committee (CEC).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness Endpoint: Technical Success</title>
        <description>Technical success is defined by ≤50% diameter stenosis after atherectomy with the Revolution™ Peripheral Atherectomy System and prior to adjunctive therapy, as measured by the independent core laboratory on the post-atherectomy contrast angiogram. Effectiveness will be assessed for investigator-identified target lesions and will be calculated as a binary variable as the percentage of target lesions with technical success.</description>
        <time_frame>1-Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness Endpoint: Technical Success</title>
          <description>Technical success is defined by ≤50% diameter stenosis after atherectomy with the Revolution™ Peripheral Atherectomy System and prior to adjunctive therapy, as measured by the independent core laboratory on the post-atherectomy contrast angiogram. Effectiveness will be assessed for investigator-identified target lesions and will be calculated as a binary variable as the percentage of target lesions with technical success.</description>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR) Rate</title>
        <description>Target Lesion Revascularization (TLR) rate through 30 days.</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR) Rate</title>
          <description>Target Lesion Revascularization (TLR) rate through 30 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in % Stenosis</title>
        <description>Change in % stenosis after treatment with Revolution™ Peripheral Atherectomy System, determined after atherectomy and prior to other adjunctive therapies, as measured by the angiographic core laboratory.</description>
        <time_frame>1-Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in % Stenosis</title>
          <description>Change in % stenosis after treatment with Revolution™ Peripheral Atherectomy System, determined after atherectomy and prior to other adjunctive therapies, as measured by the angiographic core laboratory.</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success as defined by target lesion residual stenosis of &lt;30% at the conclusion of the index procedure, after atherectomy and any adjunctive endovascular treatment, as measured by the angiographic core laboratory.</description>
        <time_frame>1-Day</time_frame>
        <population>132 total lesions in the Per Protocol dataset. Images missing for 2 lesions; calibration missing for 3 lesions therefore only 127 post procedure angiograms available.</population>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success as defined by target lesion residual stenosis of &lt;30% at the conclusion of the index procedure, after atherectomy and any adjunctive endovascular treatment, as measured by the angiographic core laboratory.</description>
          <population>132 total lesions in the Per Protocol dataset. Images missing for 2 lesions; calibration missing for 3 lesions therefore only 127 post procedure angiograms available.</population>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of the Combined Components of the Primary Safety Endpoint, Freedom From MAE</title>
        <description>Assessment of the total combined components of the primary safety endpoint (Freedom from MAE); including all-cause mortality, major target limb amputation, clinically significant distal embolization, major target vessel perforation requiring surgical or endovascular repair, and clinically-driven TLR, measured through 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the Combined Components of the Primary Safety Endpoint, Freedom From MAE</title>
          <description>Assessment of the total combined components of the primary safety endpoint (Freedom from MAE); including all-cause mortality, major target limb amputation, clinically significant distal embolization, major target vessel perforation requiring surgical or endovascular repair, and clinically-driven TLR, measured through 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Target Lesion Revascularization (TLR) Rate</title>
        <description>Freedom from Target Lesion Revascularization (TLR) rate through 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Target Lesion Revascularization (TLR) Rate</title>
          <description>Freedom from Target Lesion Revascularization (TLR) rate through 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Myocardial Infarction</title>
        <description>Freedom from Myocardial infarction through 30 days.</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Myocardial Infarction</title>
          <description>Freedom from Myocardial infarction through 30 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Myocardial Infarction</title>
        <description>Freedom from Myocardial infarction through 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Myocardial Infarction</title>
          <description>Freedom from Myocardial infarction through 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Target Vessel Revascularization (TVR) Rate</title>
        <description>Freedom from incidence of target vessel revascularization (TVR) through 30 days.</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Target Vessel Revascularization (TVR) Rate</title>
          <description>Freedom from incidence of target vessel revascularization (TVR) through 30 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Target Vessel Revascularization (TVR) Rate</title>
        <description>Freedom from incidence of target vessel revascularization (TVR) through 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Target Vessel Revascularization (TVR) Rate</title>
          <description>Freedom from incidence of target vessel revascularization (TVR) through 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Angiographic Procedural Distal Embolization</title>
        <description>Freedom from angiographic procedural distal embolization (symptomatic) in the target limb as confirmed angiographically by the core laboratory.</description>
        <time_frame>1-Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Angiographic Procedural Distal Embolization</title>
          <description>Freedom from angiographic procedural distal embolization (symptomatic) in the target limb as confirmed angiographically by the core laboratory.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Primary patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
        <time_frame>30 Days, 6 months</time_frame>
        <population>Among the 132 lesions in the Per Protocol dataset, four were excluded from the patency analyses due to missing post-atherectomy angiograms, leaving 128 lesions in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Primary patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
          <population>Among the 132 lesions in the Per Protocol dataset, four were excluded from the patency analyses due to missing post-atherectomy angiograms, leaving 128 lesions in the analysis.</population>
          <units>Percentage of primary patency</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Primary Patency</title>
        <description>Primary-assisted patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
        <time_frame>30 Days, 6 months</time_frame>
        <population>Among the 132 lesions in the Per Protocol dataset, four were excluded from the patency analyses due to missing post-atherectomy angiograms, leaving 128 lesions in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Primary Patency</title>
          <description>Primary-assisted patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
          <population>Among the 132 lesions in the Per Protocol dataset, four were excluded from the patency analyses due to missing post-atherectomy angiograms, leaving 128 lesions in the analysis.</population>
          <units>Percentage of assisted primary patency</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Number of Per protocol lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Per protocol lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>Secondary patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
        <time_frame>30 Days, 6 months</time_frame>
        <population>Among the 132 lesions in the Per Protocol dataset, four were excluded from the patency analyses due to missing post-atherectomy angiograms, leaving 128 lesions in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Revolution Treatment Arm</title>
            <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <description>Secondary patency of the target lesion at 30 days and 6 months, determined by duplex ultrasound or angiography.</description>
          <population>Among the 132 lesions in the Per Protocol dataset, four were excluded from the patency analyses due to missing post-atherectomy angiograms, leaving 128 lesions in the analysis.</population>
          <units>Percentage of secondary patency</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Number of Per protocol lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Per protocol lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Revolution Treatment Arm</title>
          <description>This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.&#xD;
Revolution™ Peripheral Atherectomy System: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>All-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Major target limb amputation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Clinically Driven TLR</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Perforation of target vessel</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Distal embolization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Product issues</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Valentis</name_or_title>
      <organization>Rex Medical</organization>
      <phone>610-629-6051</phone>
      <email>cvalentis@rexmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

